% | $
Quotes you view appear here for quick access.

OxySure Therapeutics, Inc. Message Board

  • paul462123 paul462123 Dec 13, 2013 2:34 PM Flag

    Taglich Brothers released an updated research report on OxySure

    New York, NY - December 12, 2013:

    Taglich Brothers released an updated research report on OxySure Systems, Inc. (OXYS) reiterating a Speculative Buy rating and maintaining a 12-month price target of $2.10.

    The report noted the following key investment considerations: OxySure's oxygen generating technology has lifesaving potential in the treatment of cardiac arrest, acute asthma or pneumonia, severe trauma, smoke inhalation, carbon monoxide poisoning and air embolism. Untrained nonmedical personnel using the OxySure Model 615 can provide emergency therapy safely and rapidly, supporting lifesaving resuscitation before the arrival of emergency medical personnel.

    OXYS' Model 615, easy to use and quickly brought to bear, is a highly suitable companion for automatic external defibrillators (AEDs). There are an estimated 2.2 million AEDs in service worldwide, roughly 60% of them in the US. OxySure aims to position the Model 615 alongside AEDs in public and private venues.
    We project a revenue ramp from $2 million in 2013 to $4.9 million in 2015.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • why believe taglich---------in the footnote you will see it is paid research. You might as well predict they will be bought by Apple.

    • Paul - you forgot to include the footnote that shows how much you paid for this "research".

      Direct copy and paste from the fine print of the report:
      "In June 2013 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of three more months for such services."

      So, let's make sure Philyfury and crew all understand this... The company is paying $18,000 a year to have a research firm no one's ever heard of issue these "reports" that the company actually writes for the so-called "Analyst" in order to make it look like there's someone who believes the stock is undervalued. And this is how a company very short on capital and forecasting cash burns for at least the next 2+ years is choosing to spend their money?? I just want you guys to soak that in for a minute...because when your stock loses all its value, you need to realize this is where Julian thought it best to spend your money.

      Sentiment: Strong Sell

0.031+0.003(+10.91%)May 27 3:48 PMEDT